Sartorius Stedim stock heads into the open after a 1.6% gain

At the close on September 8, 2026, Sartorius Stedim stock finished at EUR 186.30 on Euronext Paris, up 1.6%. The shares traded above their 52-week low and remained well below the 52-week high as Barclays lifted its price target to EUR 240 that day.

Sartorius Stedim stock closed at EUR 186.30 on Euronext Paris on September 8, 2026, representing a gain of 1.6% compared with the prior session. The close left the shares well above their 52-week low and still below the 52-week high, highlighting room between the current price and recent extremes.

September 8, 2026 in numbers

Sartorius Stedim Biotech SA (ISIN FR0013154002) ended the Euronext Paris session on September 8, 2026 at EUR 186.30, with the move on that day corresponding to a 1.6% advance versus the previous close, according to exchange data cited in a recent market wrap. As ad-hoc-news reported on September 10, 2026, Barclays raised its price target for the shares from EUR 210 to EUR 240 while reiterating an Overweight rating, with the stock closing that day at EUR 186.30 and therefore about 28% below the new target.

The same report noted that on Euronext Paris the shares most recently traded between a 52-week low of EUR 150.90 and a 52-week high of EUR 223.30 as of September 8, 2026, placing the close of EUR 186.30 comfortably above the low but still appreciably under the high. Per the figures cited by ad-hoc-news, the stock’s level on September 8, 2026 left an upside gap of close to 28% relative to the revised EUR 240 target, underlining that the analyst revision was a key driver for the session.

Today’s catalysts

There were no company results or corporate events for Sartorius Stedim Biotech SA explicitly scheduled for September 11, 2026 in the earnings overview for this week, with the stock instead heading into today’s session under the continued influence of the Barclays rating and target change from earlier in the week, as highlighted by ad-hoc-news. Broader market earnings and macroeconomic releases listed for September 11, 2026 in the general calendar on Yahoo Finance may shape overall sentiment for European healthcare and biopharma names today, forming part of the backdrop against which Sartorius Stedim stock will trade ahead of the Paris open.